ArticlePacing and clinical electrophysiology : PACE2026
First Report on Atrial Leadless Pacing in an Extra-Cardiac Fontan Patient.
Article in Pacing and clinical electrophysiology : PACE, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No reports on atrial leadless pacing have been demonstrated in patients with the extra-cardiac Fontan palliation. We present a case of a patient with an extra-cardiac Fontan and an alternative to pacing for symptomatic bradycardia in the setting of sinus node dysfunction. After internal review board approval, a retrospective case review was performed with follow-up of atrial leadless pacing in a patient with an extra-cardiac Fontan. A 19-year-old male with a medical history of dextro-transposition of the great arteries and valvar and sub-valvar pulmonary stenosis, hypoplastic pulmonary arteries, and an aberrant right coronary artery with eventual Glenn and Fontan palliation had intermittent sinus pauses with a failing epicardial pacemaker system. Given extremely low impedance values and eventual unipolar phrenic pacing after failed bipolar capture, he underwent an atrial pacing study and leadless pacemaker implant. Implant values demonstrated an atrial threshold of 5.5 V at 0.4 ms, impedance at 550 ohms, and sensing at < 1 mV. He was programmed AAIR (VVIR) 60 bpm and discharged on Xarelto 20 mg once a day. Follow-up at 3 months demonstrated no intracardiac thrombus, 8% atrial pacing, threshold of 2.0 V@0.4 ms, impedance of 470 ohms, and R-wave of 1 mV. The estimated device longevity was 17.9 years at last follow-up. Atrial leadless pacing is feasible in the extracardiac Fontan patient from outside of the atrium with higher but acceptable capture threshold, without complication. Larger patient population data sets are needed to assess the safety of this type of pacing long-term.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.